Objective: Comorbid ADHD and substance use disorder (SUD) presents frequently in adolescence, a developmental period that may promote the emergence of substance misuse among individuals with ADHD. Comorbid ADHD and SUD in adolescence results in significant and unique treatment challenges, necessitating examination into effective interventions. Method: This systematic review examined existing research into the treatment of comorbid adolescent ADHD and SUD. Results: Findings from a small number of pharmacological intervention studies suggest potential efficacy of extended-release stimulant and nonstimulant medications. Efficacy of psychotherapeutic interventions has not been systematically examined. Conclusion: Current research on treatments for comorbid ADHD and SUD in adolescence is limited. Future placebo-controlled clinical trials using large samples are needed to examine the efficacy of psychotherapeutic interventions, the heightened risk of prescription stimulant misuse, and the long-term maintenance of treatment gains in this population. Clinical guidelines for the treatment of comorbid ADHD and SUD are discussed.
Objective: Comorbid ADHD and substance use disorder (SUD) presents frequently in adolescence, a developmental period that may promote the emergence of substance misuse among individuals with ADHD. Comorbid ADHD and SUD in adolescence results in significant and unique treatment challenges, necessitating examination into effective interventions. Method: This systematic review examined existing research into the treatment of comorbid adolescent ADHD and SUD. Results: Findings from a small number of pharmacological intervention studies suggest potential efficacy of extended-release stimulant and nonstimulant medications. Efficacy of psychotherapeutic interventions has not been systematically examined. Conclusion: Current research on treatments for comorbid ADHD and SUD in adolescence is limited. Future placebo-controlled clinical trials using large samples are needed to examine the efficacy of psychotherapeutic interventions, the heightened risk of prescription stimulant misuse, and the long-term maintenance of treatment gains in this population. Clinical guidelines for the treatment of comorbid ADHD and SUD are discussed.
Authors: William O Cooper; Laurel A Habel; Colin M Sox; K Arnold Chan; Patrick G Arbogast; T Craig Cheetham; Katherine T Murray; Virginia P Quinn; C Michael Stein; S Todd Callahan; Bruce H Fireman; Frank A Fish; Howard S Kirshner; Anne O'Duffy; Frederick A Connell; Wayne A Ray Journal: N Engl J Med Date: 2011-11-01 Impact factor: 91.245
Authors: Slavica K Katusic; William J Barbaresi; Robert C Colligan; Amy L Weaver; Cynthia L Leibson; Steven J Jacobsen Journal: J Child Adolesc Psychopharmacol Date: 2005-10 Impact factor: 2.576
Authors: Ramon Solhkhah; Timothy E Wilens; Jeanine Daly; Jefferson B Prince; Stephanie L Van Patten; Joseph Biederman Journal: J Child Adolesc Psychopharmacol Date: 2005-10 Impact factor: 2.576
Authors: Paula D Riggs; Shannon K Hall; Susan K Mikulich-Gilbertson; Michelle Lohman; Ashley Kayser Journal: J Am Acad Child Adolesc Psychiatry Date: 2004-04 Impact factor: 8.829
Authors: Kelli Scott; Sara J Becker; Sarah A Helseth; Ian J Saldanha; Ethan M Balk; Gaelen P Adam; Kristin J Konnyu; Dale W Steele Journal: Fam Pract Date: 2022-03-24 Impact factor: 2.290
Authors: Patricia A Goodhines; Lea E Taylor; Michelle J Zaso; Kevin M Antshel; Aesoon Park Journal: Subst Use Misuse Date: 2020-08-04 Impact factor: 2.164